660 — Wai Chun Bio Technology Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsHighly SpeculativeMicro CapNeutral

Annual income statement for Wai Chun Bio Technology, fiscal year end - June 30th, HKD millions except per share, conversion factor applied.

	2020 December 31st	2022 June 30th	2023 June 30th	2024 June 30th	2025 June 30th
Period Length:	12 M	18 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	568	1,007	774	370	377
Cost of Revenue
Gross Profit	48.9	90.2	50.4	34.2	36
Selling / General / Administrative Expenses
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	558	982	762	430	372
Operating Profit	9.53	24.7	11.4	-60.3	4.72
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1.61	3.78	-5.7	-78.2	-8.93
Provision for Income Taxes
Net Income After Taxes	0.995	-1.39	-10.1	-65.7	-10.7
Minority Interest
Net Income Before Extraordinary Items
Net Income	-8.15	-21.5	-15.4	-44.2	-14.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-8.15	-21.5	-15.4	-44.2	-14.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.05	-0.096	-0.091	-0.037	-0.078
Dividends per Share
Special Dividends per Share